AZD2461: Next-Generation PARP Inhibitor for Breast Cancer and Drug Resistance Models

Executive Summary:
AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor, exhibiting an IC50 of 5 nM against PARP-1 in vitro (ApexBio). It induces G2-phase cell cycle arrest and reduces viability in MCF-7 and SKBR-3 breast cancer cell lines in a time- and concentration-dependent manner (Schwartz 2022). In vivo, AZD2461 inhibits PARP activity in mouse KB1P tumor models, with pharmacodynamic effects lasting several hours. Critically, AZD2461 has low affinity for P-glycoprotein (Pgp), providing a mechanistic basis for overcoming Pgp-mediated drug resistance. Long-term studies show AZD2461 is well tolerated and extends relapse-free survival in tumor-bearing mice (DOI).

Biological Rationale

Poly (ADP-ribose) polymerase enzymes, especially PARP-1, are central to cellular DNA repair, specifically in single-strand break repair via the base excision repair pathway. Inhibiting PARP-1 impairs the repair of DNA damage, leading to cell cycle arrest or apoptosis in cells reliant on this pathway, such as BRCA1-deficient breast cancer models (Schwartz 2022). This rationale underpins the use of PARP inhibitors in oncology, where synthetic lethality can be exploited.

Mechanism of Action of AZD2461

AZD2461 is a small-molecule inhibitor targeting the catalytic activity of PARP-1 through competitive binding at its NAD+ site, with a measured IC50 of 5 nM in biochemical assays (Product Dossier). The chemical structure of AZD2461 (C₂₂H₂₂FN₃O₃, MW 395.43) includes a phthalazinone core and a fluoro-methoxypiperidine substitution, contributing to its specificity and pharmacokinetic profile.

Upon cellular uptake, AZD2461 inhibits PARP-1 enzymatic activity, leading to accumulation of DNA single-strand breaks. This stalls replication forks, resulting in G2-phase cell cycle arrest and, ultimately, cell death in susceptible tumor cells. In preclinical breast cancer models, AZD2461 reduces the proportion of cells in S-phase and increases G2-phase populations after 48–72 hours at concentrations from 5–50 μM (Schwartz 2022).

Unlike first-generation PARP inhibitors (e.g., olaparib), AZD2461 demonstrates lower affinity for P-glycoprotein (Pgp), the major efflux transporter responsible for multidrug resistance (Olaparib.net article). This confers a strategic advantage in tumors with high Pgp expression.

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 enzymatic activity with an IC50 of 5 nM (in vitro, 25°C, buffer pH 7.5) (ApexBio).
• Reduces viable cell numbers in MCF-7 and SKBR-3 breast cancer cell lines in a dose-dependent manner (5–50 μM, 48–72 h) (Schwartz 2022).
• Induces cell cycle arrest: G2-phase fraction increases, S-phase fraction decreases (MCF-7 cells, 48 h, 10 μM) (Schwartz 2022).
• In vivo: In KB1P tumor-bearing mice, PARP inhibition persists for several hours post-injection (10 mg/kg, i.p.), with PAR levels normalized at 24 h (Schwartz 2022).
• Displays significantly lower P-glycoprotein affinity vs. olaparib, indicating reduced efflux and enhanced retention in Pgp-overexpressing cells (Olaparib.net).
• Long-term dosing (10 mg/kg, qd, 21 days) is well tolerated and extends median relapse-free survival in tumor models (Schwartz 2022).

This article extends AZD2461: Novel PARP Inhibitor Empowering Breast Cancer Research by providing updated quantitative benchmarks and a detailed mechanism-of-action mapping. For a focus on workflow protocols, see AZD2461: Novel PARP Inhibitor Advancing Breast Cancer Research, which is complemented here with specific in vivo tolerability and pharmacodynamics data.

Common Pitfalls or Misconceptions

• AZD2461 does not reverse resistance in all tumor types; its advantage over olaparib is specific to Pgp-mediated efflux, not other resistance mechanisms.
• It is not effective in cell lines or tumors with intact homologous recombination repair (e.g., BRCA1/2 wild-type).
• AZD2461 is insoluble in water; improper solvent selection (e.g., aqueous buffers) leads to precipitation and poor bioavailability.
• PARP inhibition by AZD2461 is transient in vivo; pharmacodynamic effects last several hours but not beyond 24 hours without repeated dosing.
• Exceeding recommended concentrations (>50 μM in vitro) or extended use of DMSO/ethanol stock solutions can compromise experimental reproducibility.

Applications, Limits & Misconceptions

AZD2461 is validated for use in breast cancer research, especially in BRCA1/2-mutated or Pgp-overexpressing tumor models. It is applied in cell viability, cell cycle, and DNA damage assays, typically at 5–50 μM for 48–72 hours in vitro (Schwartz 2022). In vivo, dosing regimens of 10 mg/kg daily have shown efficacy and tolerability.

Limitations include limited efficacy in homologous recombination-proficient tumors, transient pharmacodynamics, and poor aqueous solubility. Misconceptions include overextending its use to all drug-resistant cancers or assuming long-term stability in solution.

Workflow Integration & Parameters

For cell-based assays, AZD2461 is dissolved in DMSO (≥16.35 mg/mL) or ethanol with ultrasonic assistance (≥45.2 mg/mL). Working concentrations range from 5 to 50 μM, with incubation times of 48–72 hours. For in vivo studies, solutions are freshly prepared, and storage is at -20°C. The compound is suitable for use in human breast cancer lines (MCF-7, SKBR-3) and mouse KB1P tumor models.

Comparative studies may use olaparib as a reference; AZD2461's lower Pgp affinity can be demonstrated using matched Pgp-overexpressing and parental cell lines. For protocol optimization and troubleshooting, see AZD2461: Novel PARP Inhibitor Transforming Breast Cancer Research, which this article updates by clarifying pharmacodynamic duration and tolerability benchmarks.

Conclusion & Outlook

AZD2461 is a robust tool for dissecting PARP signaling and drug resistance mechanisms in breast cancer research. Its low Pgp affinity and potent PARP-1 inhibition make it a preferred choice for models of acquired resistance. Ongoing work should further delineate its utility in combination therapy and clarify its spectrum of tumor selectivity. For detailed compound data, visit the AZD2461 product page.